Background Few studies have estimated the real-world economic burden such as all-cause
and follicular lymphoma (FL)-related costs and health care resource utilization (HCRU) in …

Background: A consensus is lacking on optimal treatment sequencing for follicular
lymphoma (FL), the most common indolent lymphoma. FL is incurable, and many patients …

Abstract Background and Objective The objective of this study was to estimate the lifetime
costs of patients receiving treatment for follicular lymphoma (FL) in the United States …

BACKGROUND: The cost-effectiveness analyses of follicular lymphoma (FL) treatments
have focused on the second-line rituximab maintenance in patients with relapsed FL. The …

There is limited information on the cost burden associated with follicular lymphoma (FL) and
how it compares to other non-Hodgkin lymphoma (NHL) subtypes. We examined the direct …

The addition of rituximab to cyclophosphamide, vincristine and prednisolone (CVP) for
advanced follicular lymphoma increases median time to progression by 17 months. A US …

In advanced follicular lymphoma, rituximab is currently used with chemotherapy as induction
therapy, and as maintenance monotherapy following induction in previously untreated …

Using a retrospective claims database, we estimated the economic costs of progression
among patients with follicular non-Hodgkin lymphoma (f-NHL) treated in an outpatient …

Follicular non-Hodgkin's lymphoma (FNHL), a slow-growing cancer of the immune system,
constitutes about 15–30% of all incident non-Hodgkin's lymphoma in developed countries …

Purpose Optimal therapy of follicular lymphoma (FL) is not defined. We analyzed a large
prospective cohort study to identify current demographics and patterns of care of FL in the …